Clinical trial · Observational
Lymphedema Treatment Registry
Multi Center Lymphedema Treatment Registry (LET) Study
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Patients with breast cancer related lymphedema (clinical stage 0-2) will include in this study. Patients will take their demographic and clinical history and will evaluate with measurements of extremity volumes, body mass index, quality of life status and image studies (lymphoscintigraphy, Ultrasonography (USG), Indocyanine Green (ICG) Lymphograph or magnetic resonance imaging (MRI)) before and after the complete decongestive therapy. Outcome measurements such as limb volume, quality of life questionnaire and USG will repeat every 6,12,18, 24 months.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Breast Cancer Lymphedema | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Ketoprofen | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (3)
- label
- Group 1
- description
- Complete Decongestive Therapy
- label
- Group 2
- description
- Complete Decongestive Therapy + PO Ketoprofen + Local ketoprofen gel
- interventionNames
- Drug: Ketoprofen
- label
- Group 3
- description
- Complete Decongestive Therapy + Local Ketoprofen gel
- interventionNames
- Drug: Ketoprofen
Primary outcomes (1)
- measure
- Limb Volume
- timeFrame
- 6,12,18, 24 months
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Breast cancer * Lymphedema more than 6 months * Lymphedema stage 0-2 * Completed treatment (CT-RT) Exclusion Criteria: * Stage 3 lymphedema * Cardiovasculary disease * Hepatic disease * Kidney disease * Cerebrovascular event * Metastasis * Gastritis * Infection * Smoking * Active cancer * Bleeding history
References
Publications (3)
- RESULTForte AJ, Boczar D, Huayllani MT, Lu X, McLaughlin SA. Pharmacotherapy Agents in Lymphedema Treatment: A Systematic Review. Cureus. 2019 Dec 5;11(12):e6300. doi: 10.7759/cureus.6300. PMID 31815082
- RESULTRockson SG, Tian W, Jiang X, Kuznetsova T, Haddad F, Zampell J, Mehrara B, Sampson JP, Roche L, Kim J, Nicolls MR. Pilot studies demonstrate the potential benefits of antiinflammatory therapy in human lymphedema. JCI Insight. 2018 Oct 18;3(20):e123775. doi: 10.1172/jci.insight.123775. PMID 30333315
- RESULTNakamura K, Radhakrishnan K, Wong YM, Rockson SG. Anti-inflammatory pharmacotherapy with ketoprofen ameliorates experimental lymphatic vascular insufficiency in mice. PLoS One. 2009 Dec 21;4(12):e8380. doi: 10.1371/journal.pone.0008380. PMID 20027220